FDA warned OptiHealth Products over website claims that Super Antioxidant (OPCXtra) is a drug for diseases like diabetes and Alzheimer's.
What happened
FDA reviewed optihealthproducts.com in December 2025 and the company's Facebook page, which sends consumers to the website. FDA found claims that Super Antioxidant (OPCXtra) and bilberry/OPC antioxidants lower heart disease risk, help regulate blood sugar, and address macular degeneration, Alzheimer's, and Parkinson's. FDA says those claims make the product an unapproved new drug and a misbranded drug lacking adequate directions for use.
What FDA found
FDA says website claims that Super Antioxidant (OPCXtra) can reduce disease risk or treat diseases make it a drug intended for disease use.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]FDA says the product is a new drug—not generally recognized as safe and effective for those uses and not FDA-approved—so it cannot be sold across state lines without approval.
section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]FDA says the product is misbranded (lacking adequate directions for safe lay use) because its intended diseases are not suitable for self-diagnosis or self-treatment.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA says introducing the misbranded drug into interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks OptiHealth to notify it in writing within 15 working days of steps taken to address the violations and prevent recurrence, including documentation. If corrective actions cannot be completed in that time, the company must explain the delay and provide a completion date.
Who should pay attention
- Dietary supplement brands making disease-related claims online
- Marketing and e-commerce teams for supplement websites and social media
- Sellers of antioxidant, bilberry, or OPC products
This is a summary. Read the original letter on fda.gov.